Patents by Inventor Jiaping Peng

Jiaping Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST GPC3 AND USES THEREOF
    Publication number: 20240368303
    Abstract: Disclosed herein are antibodies against GPC3 and uses thereof, specifically monoclonal antibodies against GPC3, bispecific antibodies against GPC3 and CD3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates comprising the antibodies, and therapeutic methods for using the antibodies.
    Type: Application
    Filed: December 23, 2021
    Publication date: November 7, 2024
    Applicant: ZHEJIANG SHIMAI PHARMACEUTICAL CO., LTD.
    Inventors: Zuoxiang Xiao, Jiaping Peng, Dongwen Zhou, Wei Zhou, Hangbin Miao, Guannv Wang
  • ANTIBODIES AGAINST ROR1 AND USES THEREOF
    Publication number: 20240309116
    Abstract: Disclosed herein are monoclonal antibodies against ROR1, bispecific antibodies against ROR1 and CD3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and antibody-drug conjugates comprising the antibodies, and therapeutic methods for using the antibodies.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 19, 2024
    Applicant: Zhejiang Shimai Pharmaceutical Co., Ltd.
    Inventors: Zuoxiang Xiao, Jiaping Peng, Dongwen Zhou, Wei Zhou, Hangbin Miao, Guannv Wang
  • Therapeutic use of antibodies against ENPP3
    Patent number: 11766479
    Abstract: Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: September 26, 2023
    Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.
    Inventors: Zuoxiang Xiao, Jiaping Peng, Dongwen Zhou, Wei Zhou
  • Antibodies against ENPP3 and uses thereof
    Patent number: 11578139
    Abstract: Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: February 14, 2023
    Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.
    Inventors: Zuoxiang XIao, Jiaping Peng, Dongwen Zhou, Wei Zhou